Study shows Naltrexone could quickly reduce alcohol dependence in patients
NEW YORK According to a new study, Naltrexone, an anti-addiction medication, may reduce drinking in patients dependant on alcohol within two days of treatment.
The study, conducted at the Boston University School of medicine, used 600 men and women who were alcohol-dependant and injected them with naltrexone XR, as well as 12 sessions of low-intensity psychosocial therapy, according to published reports.
The result of the study was that, compared with the control group who received a placebo, patients that received a high dose of naltrexone experienced a significant reduction of drinking by the third day of injection.
Twenty percent of the patients who received a high dose reported heavy drinking as opposed to the 35 percent who received the placebo. Patients given a lower dose of Naltrexone did experience reductions but not at a significant level.
New combination of drugs shown favorable in treating lupus
NEW YORK A new study suggests that a combination of two potent drugs may serve as a new treatment for those who don’t respond to conventional Lupus treatments.
In the study, Ronald van Vollenhoven and colleagues at Karolinska University Hospital in Stockholm tested 16 female patients who did not respond to traditional lupus treatment, and were given, as a result, weekly infusions of rituximab for 4 weeks. The first and last infusions were combined with cyclophosphamide and a steroid, according to published reports.
It was found that after 6 months there was a significant decrease of SLE severity also known as systemic lupus erythematosus, which is an autoimmune disorder that damages the joints, kidneys, heart, lungs and blood.
Researchers noted that the presence of rituximab which targets B cells of the immune system, and cyclophsophamide, a strong immune suppressant drug, showed 50 percent improvement in disease severity, as well as causing the disease to go to remission in nine out of the thirteen patients.
Amgen, Roche battle over Mircera still unsettled
In the long battle for Amgen to prevent generic drug company Roche Holdings from bringing its anemia drug Mircera into the US market, a federal appeals court has ruled that Roche could import its drug as long as it was not for sale, while also returning the case back to the International Trade Commission.
Amgen feels that since Roche applied for Mircera’s approval from the FDA, it was violating Amgen’s patents—for Epogen and Aranesp—because the application proved intent to sell. The FDA has already approved the drug but, according to published reports, it has not been marketed it in the US based on the legal matters involved.
As Drug Store News reported yesterday, Roche agreed to the U.S. District Court for Massachusetts’ conditions in an attempt to get Mircera on the market, including, according to published reports, paying Amgen a higher royalty fee. The court’s approval would give Amgen a new rival in the top selling Anemia market, which has made up more than 40 percent of Amgen’s revenue per year. Roche has agreed to set Mircera’s price at or below Epogen’s for the remainder of the patents that Amgen holds.
Amgen’s patents for its anemia drugs begin expiring in 2013, and, according to reports, Roche plans on waiting until then to sell its drug in the U.S. According to IMS Health, Aranesp had U.S. sales of $3.2 billion last year and Epogen had sales of $3.1 billion.